Briefs archive
Every milestone from our business network, newest first
November 2026
7 Nov 2026 · Weekly press review
Press review: news from the people on Beginner’s Mind, 7 Nov 2026 →
26 milestones from guests of the show, first edition covering the last twelve months
4 Nov 2026 · BIOGENA
Nordic combined athlete Franz-Josef Rehrl extends his BIOGENA SPORTS partnership and now jumps on BIOGENA skis ↗
Source: BIOGENA (press release in German)
4 Nov 2026 · PHNIX Innovation Institute
Debra Houry named founding director of the new PHNIX Innovation Institute in California ↗
Source: Renaissance Philanthropy · Guest: Debra Houry
October 2026
26 Oct 2026 · DMC / Sofinnova
DMC raises $18 million in a round co-led by Sofinnova ↗
Source: Sofinnova Partners · Guest: Joško Bobanović
20 Oct 2026 · Insilico Medicine
Insilico reaches its first Servier milestone and its first profitable half-year ↗
Source: Insilico Medicine · The conversation
7 Oct 2026 · Last Energy
US Energy Department approves the final safety analysis for Last Energy’s pilot reactor ↗
Source: Last Energy · Guest: Bret Kugelmass
September 2026
22 Sep 2026 · European Investment Bank
EU and EIB launch an investors pact for European tech scale-ups ↗
Source: EIB · The conversation
15 Sep 2026 · Ori Biotech
Ori Biotech signs a ten-year partnership worth up to $120 million ↗
Source: Ori Biotech via Business Wire · Guest: Jason Foster
10 Sep 2026 · Insilico Medicine
First patient dosed in Phase III of rentosertib, the AI-designed drug for lung fibrosis ↗
Source: Insilico Medicine · The conversation
8 Sep 2026 · Sycai Medical / Ship2B
Ship2B portfolio company Sycai wins the CE mark for its AI liver tool ↗
Source: Ship2B Ventures · Guest: Jordi Ferrer Rendé
July 2026
15 Jul 2026 · LMU Munich
LMU Innovation Incubator wins second prize at the MöglichMacher award ↗
Source: LMU Munich · The conversation
December 2025
30 Dec 2025 · Insilico Medicine
Insilico lists in Hong Kong in the year’s largest biotech IPO there ↗
Source: BioSpectrum Asia
June 2025
5 Jun 2025 · Immunic
Immunic completes enrolment of 2,221 patients in its Phase 3 MS trials; data due by the end of 2026 ↗
Source: Immunic · Guest: Daniel Vitt, EP 115